Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oruka TherapeuticsORKA -0.74%14 Buyback Yield % is -0.73 as of Jul. 27, 2026. GuruFocus rates ORKA with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 737 Biotechnology companies, Oruka Therapeutics ranks better than 74.36% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Oruka Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Oruka Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORKA vs DNTH, SRRK, DFTX: Buyback Yield % Comparison
For the Biotechnology subindustry, Oruka Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oruka Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Oruka Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oruka Therapeutics (ORKA) has a Buyback Yield % of -0.73 as of Jul. 27, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Oruka Therapeutics and its competitors. According to the industry distribution chart, Oruka Therapeutics ranks #189 out of 737 companies in the Biotechnology industry, placing it in the top 25.6%.
Is Oruka Therapeutics' Buyback Yield % too high?
Oruka Therapeutics' current Buyback Yield % is -0.73. Based on the distribution chart, Oruka Therapeutics ranks #189 out of 737 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oruka Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Oruka Therapeutics' Buyback Yield % compare to DNTH and SRRK?
According to the Biotechnology industry distribution chart, Oruka Therapeutics ranks #189 out of 737 companies for Buyback Yield %. This puts Oruka Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Oruka Therapeutics and its competitors. Oruka Therapeutics's current Buyback Yield % is -0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oruka Therapeutics stock overvalued right now?
Oruka Therapeutics (ORKA) has a current Buyback Yield % of -0.73. The current Buyback Yield % is -0.73. Oruka Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Oruka Therapeutics (ORKA), the current Buyback Yield % is -0.73 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
14GF Score
Get the complete analysis for ORKA
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORKA has been successfully added to your 
